Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation

AAPS PharmSciTech

Volumn 8, Issue 4, 2007, Pages

  Abdelkader, Hamdy ^a   Abdalla, Ossama Youssef ^b   Salem, Hesham ^a  

^a Minia University   (Egypt)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Baclofen; Drug excipient compatibility; Hydrophilic matrix; Modified release

Indexed keywords

ALGINIC ACID; BACLOFEN; CARBOXYMETHYLCELLULOSE; EXCIPIENT; METHYLCELLULOSE; POLYMER; CENTRAL MUSCLE RELAXANT; DRUG CARRIER; GLUCURONIC ACID; HEXURONIC ACID;

ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG GRANULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; HYDROPHILICITY; IN VITRO STUDY; MATRIX TABLET; PHYSICAL CHEMISTRY; REPRODUCIBILITY; SHELF LIFE; TABLET COMPRESSION; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET THICKNESS; THERMAL ANALYSIS; CHEMISTRY; DELAYED RELEASE FORMULATION; HARDNESS; KINETICS; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; SOLUBILITY; TABLET;

ADMINISTRATION, ORAL; ALGINATES; BACLOFEN; CALORIMETRY, DIFFERENTIAL SCANNING; CARBOXYMETHYLCELLULOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; GLUCURONIC ACID; HARDNESS; HARDNESS TESTS; HEXURONIC ACIDS; KINETICS; METHYLCELLULOSE; MUSCLE RELAXANTS, CENTRAL; POLYMERS; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 37249065213     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0804100     Document Type: Article

References (40)

1. Theeuwes F. Oros osmotic system development. Drug Dev Ind Pharm. 1983;9:1331-1357.
2. Ahuja S. Analytical Profiles of Drug Substances and Excipients. London, UK: Academic Press; 1985:527-548.
3. Merino M, Peris RJ, Torres MF, Sanchez PA, Carbonell MC, Casabo VG. Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. Biopharm Drug Dispos. 1989;10:279-297.
4. Cejudo-Ferragud E, Nácher A, Polache A, Cercos-Fortea T, Merino MC, Casabó VG. Evidence of competitive inhibition for the intestinal absorption of baclofen for phenylalanine. Int J Pharm. 1996;132:63-69.
5. Hugenholtz H, Nelson RF, Dehoux E. Intrathecal baclofen: the importance of catheter position. Can J Neurol Sci. 1993;20:165-170.
6. Martindale. Martindale: The Complete Drug Reference. Chicago, IL: Pharmaceutical Press; 2005:1758-1759.
7. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimization in the treatment of Parkinson's disease. Clin Pharmacokinet. 1996; 30:463-481.
8. Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol. 1987;27:21-27.
9. Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC. Pharmaceutical design and development of a Sinemit controlled release formulation. Neurology. 1989;39:20-24.
10. Yeh KC, August TF, Bush DF. Pharmacokinetics and bioavailability of Sinemit CR: a summary of human studies. Neurology. 1989; 39:25-38.
11. LeWitt PA, Nelson MV, Berchou RC. Controlled-release carbidopa/levodopa (Sinemit 50/200 CR4): clinical and pharmacokinetic studies. Neurology. 1989;39:45-53.
12. Crevoisier C, Hoevels B, Zürcher G, Da Prada M. Bioavailability of 1-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol. 1987;27:36-46.
13. Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Eur Neurol. 1987;27:54-58.
14. Cruaud O, Benita S, Benoit JP. The characterization and release kinetics evaluation of baclofen microspheres designed for intrathecal injection. Int J Pharm. 1999;177:247-257.
15. Lagarce F, Renaud P, Faisnat N, et al. Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur J Pharm Biopharm. 2005;59:449-459.
16. Zierski J, Muller H, Dralle D, Wurdinger T. Implanted pump systems for treatment of spasticity. Acta Neurochir Suppl (Wien). 1988;43: 94-99.
17. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia. 1991;29:48-64.
18. Hugenholtz H, Nelson RF, Dehoux E, Birkerton R. Intrathecal baclofen for intractable spinal spasticity - a double-blind cross-over comparison of 6 patients. Can J Neurol Sci. 1992;19:188-195.
19. Hugenholtz H, Nelson RF, Dehoux E. Intrathecal baclofen: the importance of catheter position. Can J Neurol Sci. 1993;20:165-167.
20. Ritger PL, Peppas NA. A simple equation for description of solute release, II: Fickian and anomalous release from swellable devices. J Control Release. 1987;5:37-42.
21. Sato H, Miyagawa Y, Okabe T, Miyajima M, Sunada H. Dissolution mechanism of diclofenac sodium from wax matrix granules. J Pharm Sci. 1997;86:929-934.
22. Raghuram RK, Srinivas M, Srinivas R. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS PharmSciTech [serial online]. 2003;4:E61.
23. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Philadelphia, PA: Lea and Febiger; 1987: 317-318.
24. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.
25. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110-112.
26. Peppas NA, Sahlin JJ. A simple equation for the description of solute release, III: coupling of diffusion and relaxation. Int J Pharm. 1989;57:169-175.
27. Ritger PL, Peppas NA. A simple equation for description of solute release, I: Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5:23-35.
28. Talukdar MM, Rommbaut P, Kinget R. Comparative study on xanthan gum and hydroxypropyl methylcellulose as matrices for controlled-release drug delivery. Int J Pharm. 1996;129:233-241.
29. Reza MS, Abdul Quadir M, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharm Sci. 2003;6: 282-291.
30. Mockel JE, Lippold BC. Zero-order release from hydrocolloid matrices. Pharm Res. 1993;10:1066-1070.
31. Pharmaceutical Codex. Principles and Practice of Pharmaceutics. London, UK: Pharmaceutical Press; 1994:178-186.
32. O'Neil MJ, ed. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th ed. Whitehouse Station, NJ: Merck & Co; 2001:164-165.
33. Martin A, ed. Micromeritics. In: Physical Pharmacy. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:423-454.
34. Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled release dosage forms. Int J Pharm Technol Prod Manuf. 1984;5:1-9.
35. Khan KA, Rhodes CT. Evaluation of different viscosity grades of sodium carboxy methylcellulose as tablet disintegrants. Pharm Acta Helv. 1975;50:99-102.
36. Shah NH, Lazarus JH, Jarwoski CL. Carboxy methylcellulose: effect of degree of polymerization and substitution on tablet disintegration and dissolution. J Pharm Sci. 1981;70:611-613.
37. Al-Hmoud H, Efentakis M, Choulis NH. A controlled release matrix using a mixture of hydrophilic and hydrophobic polymers. Int J Pharm. 1991;68:R1-R3.
38. Esmail MN, Yousry ME, Sayed HK. Effect of accelerated storage conditions on the dissolution and bioavailability of amitriptyline from sustained-release capsules. SPJ. 1996;4:92-98.
39. Braco SA, Lamas MC, Salamon CJ. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Pharm Sci. 2002;5:213-219.
40. Goetz CG, Tanner CM, Carrol VS. Controlled-release Sinemet. Neurology. 1987;37:1567-1575.